retatrutide and menopause Reta Weight Loss: Phase 3 Trial Data What Patients Actually Report in 2026 Retatrutide for Women Over 40:
Description
[DOI] [Google Scholar] 3.Ard J., Fitch A., Fruh S., Herman L
Tirzepatide is a dual GLP-1/GIP agonist (two targets)
doi: 10.1248/cpb.40.1366
Prescription trends show particularly rapid growth for newer agents
These pleiotropic effects include the reduction of BW and BP, the improvement of lipid metabolism and a spectrum of cardioprotective effects
